IGFBP-3 promoter polymorphism -202A>C (rs2854774) contributes to prostate cancer risk: evidence based on 9,482 subjects.
Evidence suggests that insulin-like growth factor-binding protein 3 (IGFBP-3) might play a role in the carcinogenesis of prostate cancer (PCa). To date, several studies have been conducted to investigate the association between IGFBP-3 -202A>C polymorphism and PCa risk in humans. However, the results remain inconclusive and inconsistent. Hence, we performed a meta-analysis of all eligible case-control studies. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association. 16 studies from 10 articles that included a total of 4,602 PCa cases and 4,880 controls were included in the meta-analysis. The results showed that the IGFBP-3 -A>C polymorphism was associated with a significant increase in PCa risk. The variant homozygote genotype CC of IGFBP-3 -202A>C polymorphism was associated with a significantly increased risk in homozygote comparison (OR = 1.22, 95% CI = 1.07-1.38, I(2) = 36.10%) and recessive model (OR = 1.11, 95% CI = 1.00-1.22, I(2) = 15.60%). In the stratified analysis, the risk remained for studies in Asian men and hospital-based studies. These results suggested that the IGFBP-3 -202A>C polymorphism might contribute to PCa susceptibility, especially in Asian men and hospital-based studies. Further studies are needed to confirm the relationship.